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October 23, 2012:1710–4resolution of PET to define the precise locations of 18F-NaF
uptake in coronary arteries.
Finally, we do agree with Dr. Mohler and colleagues that, after
further validation, 18F-NaF PET of the coronary arteries may give
nique insights into the pathophysiology of calcium deposition and
erhaps its dispersal with appropriate therapy.
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Efficiently Doing the Wrong Thing
We would like to commend Felker and Mentz (1) for their
comprehensive review of volume removal therapy for patients with
acute decompensated heart failure (ADHF). However, we also
would like to challenge their most basic assertion that “Fluid
retention and congestion are responsible for 90% of HF hospital-
izations.” Neither of the references they cite (2,3) provide data to
support that fluid retention occurs before the onset of ADHF in most
patients. In fact, more recent studies that have measured weight gain
(as a surrogate for fluid retention) show clearly that most patients gain
either no, or minimal, weight before hospitalization for ADHF (4,5)
espite increased cardiac filling pressures (5).
To account for increased cardiac filling pressures in the absence
f weight gain, volume shifts rather than volume gains must occur.
n a recent manuscript (6), we elucidate the likely mechanisms
nderlying these shifts, which involve a normally compliant splanch-
ic venous system that becomes noncompliant and results in
edistribution of volume to the cardiopulmonary circulation, a
rocess that can occur rapidly. We also point out that even in the
inority of patients who do experience weight gain, little of the
xcess fluid resides within the effective circulatory volume (approx-
mately 2.5%). The majority of patients presenting with congestionlikely have a syndrome of sympathetically mediated redistribution
of volume and diuretic resistance.
Fluid retention and congestion do not necessarily represent the
same phenomenon, and congestion most often is not due to fluid
overload. Thus, strategies aimed at removing salt and water will
necessarily be fraught with complications, including intravascular
volume depletion, activation of the renin-angiotensin system,
worsening renal function, and iatrogenically induced cardiorenal
syndrome. Therefore, we caution readers to reconsider volume
removal as the prime target of therapy for patients with ADHF.
Diagnosing the contribution of redistribution versus total body
salt and water gain emerges as the primary decision point,
followed by therapy directed at the underlying etiology of
congestion.
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Reply
We thank Drs. Dunlap and Sobotka for their interest in our recent
review on volume removal in patients with acute decompensated
heart failure (ADHF). We agree with them that redistribution of
volume (rather than increase in total body volume) may be an
important and underappreciated mechanism in patients with
acute decompensated heart failure, as our group has suggested
previously (1).
Although we welcome “outside the box” thinking in a field that
clearly would benefit from new ideas, we also suggest that the
results from recent clinical trials might dampen the enthusiasm for
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October 23, 2012:1710–4the hypothesis that redistribution of volume is the primary patho-
physiology of most patients with ADHF. First, if redistribution
were the primary culprit of decompensation, it would follow that
vasodilator therapy would be a highly effective therapy for ADHF.
Unfortunately, the largest vasodilator trial ever performed in heart
failure, the recently completed ASCEND-HF (Acute Study of
Clinical Effectiveness of Nesiritide in Decompensated Heart
Failure) study, showed no significant clinical benefit of vasodilator
therapy (2). Secondly, the randomized, double-blinded DOSE
(Diuretic Optimization Strategies Evaluation) study suggested
greater efficacy in terms of symptom relief and decongestion with
a high-dose versus a low-dose loop diuretic regimen, without any
evidence for long-term harm on renal function or clinical end-
points (3). These data would seem to contradict the assertion that
excess volume is not an important mechanism for most patients
with ADHF and that “strategies aimed at removing salt and water
will necessarily be fraught with complications.”
Although both volume overload and volume redistribution are
likely to be operative in individual patients to varying degrees,
current diagnostic tools to not appear adequate to distinguish these
mechanisms clinically. We strongly agree with the general sugges-
tion in the final sentence of their letter that greater focus on thespecific mechanisms operative in individual patients could lead to
better individualization of therapy and better outcomes in ADHF.
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